Decreased serum human leukocyte antigen-G

Decreased serum human leukocyte antigen-G ranges are related to gestational diabetes mellitus 

Goal: This examine was designed to decide serum human leukocyte antigen-G (HLA-G) ranges and set up whether or not serum HLA-G stage is said with gestational diabetes mellitus (GDM).

Strategies: Twenty-five GDM sufferers aged between 24 and 34 years and 24 wholesome pregnant ladies aged between 22 and 33 years had been included on this examine. Well being standing of topics was decided by medical historical past, bodily, and obstetric examinations. Absence of household historical past for Sort 2 diabetes mellitus, absence of prognosis or medical proof of any main illness, and absence of remedy use altering glucose metabolism constituted the inclusion standards. GDM instances who’re at their 24-28 weeks of being pregnant and who haven’t been utilizing any oral hypoglycemic brokers had been included in GDM group. Management group consisted of wholesome pregnant ladies at their 24-28 weeks of being pregnant.

Outcomes: Ladies with GDM had considerably decrease ranges of serum HLA-G than controls. HLA-G ranges had been negatively correlated with all parameters of glucose metabolism together with insulin (r = – 0.14; p = 0.338), fasting blood glucose (r = – 0.220; p = 0.129), 1-h oral glucose tolerance take a look at (OGTT) blood glucose (r = – 0.18; p = 0.271), 2-h OGTT blood glucose (r = – 0.314; p = 0.172), homeostasis mannequin evaluation (r = – 0.226; p = 0.119), HbA1C (r = -0.342; p = 0.108), and WBC (r = -0.149; p = 0.307). There was a detrimental correlation between HLA-G and BMI (r = -0.341; p = 0.016).

Conclusion: Decreased circulating HLA-G stage is discovered to be related to insulin resistance and GDM, on this examine.

jointsjournal
jointsjournal

Mouse Carcinoembryonic Antigen (CEA) ELISA Kit

RD-CEA-Mu-48Tests 48 Tests
EUR 482.4

Mouse Carcinoembryonic Antigen (CEA) ELISA Kit

RD-CEA-Mu-96Tests 96 Tests
EUR 663.6

Carcinoembryonic Antigen (CEA)

MO47049 0.5 ml
EUR 418.8

Carcinoembryonic Antigen (CEA)

HY-P0277 5mg
EUR 1678.8

Carcinoembryonic Antigen (CEA) Antibody

20-abx102321
  • EUR 360.00
  • EUR 159.60
  • EUR 944.40
  • EUR 493.20
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx102322
  • EUR 360.00
  • EUR 159.60
  • EUR 944.40
  • EUR 493.20
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx102323
  • EUR 393.60
  • EUR 159.60
  • EUR 1095.60
  • EUR 560.40
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx102324
  • EUR 393.60
  • EUR 159.60
  • EUR 1095.60
  • EUR 560.40
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx171571
  • EUR 844.80
  • EUR 427.20
  • 1 mg
  • 200 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx171572
  • EUR 1011.60
  • EUR 526.80
  • 1 mg
  • 200 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx175703
  • EUR 410.40
  • EUR 159.60
  • EUR 1144.80
  • EUR 577.20
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

abx120020-1mg 1 mg
EUR 944.4

Carcinoembryonic Antigen (CEA) Antibody

20-abx128498
  • EUR 360.00
  • EUR 159.60
  • EUR 944.40
  • EUR 493.20
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

20-abx128499
  • EUR 360.00
  • EUR 159.60
  • EUR 944.40
  • EUR 493.20
  • EUR 309.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody

abx020536-1mg 1 mg
EUR 944.4

Carcinoembryonic Antigen (CEA) Antibody

abx020540-1mg 1 mg
EUR 944.4

Carcinoembryonic Antigen (CEA) Antibody

abx020541-1mg 1 mg
EUR 910.8

Carcinoembryonic Antigen (CEA) Antibody

abx020542-1mg 1 mg
EUR 828

Carcinoembryonic Antigen (CEA) Antibody

abx020543-1mg 1 mg
EUR 886.8

Carcinoembryonic Antigen (CEA) Antibody

abx020544-1mg 1 mg
EUR 828

Carcinoembryonic Antigen (CEA) Antibody

abx020545-1mg 1 mg
EUR 828

Carcinoembryonic Antigen (CEA) Antibody

abx020546-1mg 1 mg
EUR 828

Carcinoembryonic Antigen (CEA) Antibody

abx022526-01ml 0.1 ml
EUR 1328.4

Carcinoembryonic Antigen (CEA) Antibody

abx231576-100ug 100 ug
EUR 577.2

Carcinoembryonic Antigen (CEA) Antibody

20-abx270133
  • EUR 560.40
  • EUR 644.40
  • EUR 326.40
  • EUR 978.00
  • EUR 427.20
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody

20-abx270165
  • EUR 560.40
  • EUR 644.40
  • EUR 326.40
  • EUR 978.00
  • EUR 427.20
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody

20-abx270190
  • EUR 560.40
  • EUR 644.40
  • EUR 326.40
  • EUR 978.00
  • EUR 427.20
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Human carcinoembryonic antigen (CEA) antigen

CEA15-N-100 100 ug
EUR 270

Eukaryotic Carcinoembryonic Antigen (CEA)

4-EPA150Hu61
  • EUR 614.59
  • EUR 288.00
  • EUR 1974.72
  • EUR 738.24
  • EUR 1356.48
  • EUR 487.20
  • EUR 4756.80
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Carcinoembryonic Antigen expressed in: 293F cell

Active Carcinoembryonic Antigen (CEA)

4-APA150Hu04
  • EUR 778.02
  • EUR 331.20
  • EUR 2587.58
  • EUR 942.53
  • EUR 1765.06
  • EUR 596.40
  • EUR 6288.96
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Carcinoembryonic Antigen expressed in: Available from E.coli, Yeast, Baculovirus and Mammalian cells

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu01
  • EUR 485.57
  • EUR 253.20
  • EUR 1490.88
  • EUR 576.96
  • EUR 1033.92
  • EUR 400.80
  • EUR 3547.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu02
  • EUR 485.57
  • EUR 253.20
  • EUR 1490.88
  • EUR 576.96
  • EUR 1033.92
  • EUR 400.80
  • EUR 3547.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu03
  • EUR 485.57
  • EUR 253.20
  • EUR 1490.88
  • EUR 576.96
  • EUR 1033.92
  • EUR 400.80
  • EUR 3547.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Hu04
  • EUR 485.57
  • EUR 253.20
  • EUR 1490.88
  • EUR 576.96
  • EUR 1033.92
  • EUR 400.80
  • EUR 3547.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Mu01
  • EUR 588.79
  • EUR 280.80
  • EUR 1877.95
  • EUR 705.98
  • EUR 1291.97
  • EUR 469.20
  • EUR 4514.88
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Mu02
  • EUR 582.34
  • EUR 279.60
  • EUR 1853.76
  • EUR 697.92
  • EUR 1275.84
  • EUR 465.60
  • EUR 4454.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Carcinoembryonic Antigen expressed in: E.coli

Recombinant Carcinoembryonic Antigen (CEA)

4-RPA150Ra01
  • EUR 599.54
  • EUR 283.20
  • EUR 1918.27
  • EUR 719.42
  • EUR 1318.85
  • EUR 476.40
  • EUR 4615.68
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Rat Carcinoembryonic Antigen expressed in: E.coli

Carcinoembryonic Antigen/CEA Monoclonal Antibody

EM1061-100ul 100ul
EUR 334.8
Description: A Mouse Monoclonal antibody against Carcinoembryonic Antigen/CEA from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

Carcinoembryonic Antigen/CEA Monoclonal Antibody

EM1061-50ul 50ul
EUR 248.4
Description: A Mouse Monoclonal antibody against Carcinoembryonic Antigen/CEA from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

Carcinoembryonic Antigen (CEA) Antibody Pair

20-abx370130
  • EUR 1328.40
  • EUR 878.40
  • 10 × 96 tests
  • 5 × 96 tests

Carcinoembryonic Antigen (CEA) Antibody (FITC)

20-abx270431
  • EUR 627.60
  • EUR 727.20
  • EUR 360.00
  • EUR 1128.00
  • EUR 460.80
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (FITC)

20-abx270463
  • EUR 627.60
  • EUR 727.20
  • EUR 360.00
  • EUR 1128.00
  • EUR 460.80
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (FITC)

20-abx270488
  • EUR 627.60
  • EUR 727.20
  • EUR 360.00
  • EUR 1128.00
  • EUR 460.80
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (APC)

20-abx270663
  • EUR 844.80
  • EUR 994.80
  • EUR 444.00
  • EUR 1596.00
  • EUR 594.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (APC)

20-abx270695
  • EUR 844.80
  • EUR 994.80
  • EUR 444.00
  • EUR 1596.00
  • EUR 594.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (APC)

20-abx270720
  • EUR 844.80
  • EUR 994.80
  • EUR 444.00
  • EUR 1596.00
  • EUR 594.00
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (PE)

20-abx270895
  • EUR 727.20
  • EUR 861.60
  • EUR 393.60
  • EUR 1362.00
  • EUR 526.80
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (PE)

20-abx270927
  • EUR 727.20
  • EUR 861.60
  • EUR 393.60
  • EUR 1362.00
  • EUR 526.80
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (PE)

20-abx270952
  • EUR 727.20
  • EUR 861.60
  • EUR 393.60
  • EUR 1362.00
  • EUR 526.80
  • 100 tests
  • 200 tests
  • 25 tests
  • 500 tests
  • 50 tests

Carcinoembryonic Antigen (CEA) Antibody (Biotin)

20-abx271833
  • EUR 376.80
  • EUR 260.40
  • EUR 1028.40
  • EUR 526.80
  • EUR 326.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Carcinoembryonic Antigen (CEA) Antibody (Biotin)

20-abx272619
  • EUR 410.40
  • EUR 260.40
  • EUR 1195.20
  • EUR 594.00
  • EUR 360.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Carcinoembryonic Antigen (CEA) Protein

20-abx166414
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Carcinoembryonic Antigen (CEA) Protein

20-abx065719
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Carcinoembryonic Antigen (CEA) Protein

20-abx065720
  • EUR 828.00
  • EUR 343.20
  • EUR 2532.00
  • EUR 978.00
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Carcinoembryonic Antigen (CEA) Protein

20-abx065721
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Carcinoembryonic Antigen (CEA) Protein

20-abx065722
  • EUR 811.20
  • EUR 343.20
  • EUR 2498.40
  • EUR 961.20
  • EUR 577.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Carcinoembryonic Antigen (CEA) Protein

20-abx065723
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Carcinoembryonic Antigen (CEA) Protein

20-abx651474
  • EUR 861.60
  • EUR 343.20
  • EUR 2665.20
  • EUR 1028.40
  • EUR 610.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Carcinoembryonic Antigen (CEA) Protein

20-abx652080
  • EUR 844.80
  • EUR 343.20
  • EUR 2581.20
  • EUR 994.80
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Carcinoembryonic Antigen (CEA) ELISA

LF-EK0161 1×96T
EUR 723.6

anti-Carcinoembryonic Antigen/CEA (10E1)

LF-MA20354 100 ug
EUR 424.8
Description: Mouse monoclonal to Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen(CEA) Mouse Monoclonal Antibody

38016-100ul 100ul
EUR 302.4

Carcinoembryonic Antigen(CEA) Mouse Monoclonal Antibody

38016-50ul 50ul
EUR 224.4

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Mouse)

4-PAA150Mu01
  • EUR 246.00
  • EUR 2235.60
  • EUR 573.60
  • EUR 301.20
  • EUR 235.20
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Mouse Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Rat)

4-PAA150Hu01
  • EUR 225.60
  • EUR 1903.20
  • EUR 498.00
  • EUR 271.20
  • EUR 225.60
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Rat Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Human)

4-PAA150Hu02
  • EUR 225.60
  • EUR 1903.20
  • EUR 498.00
  • EUR 271.20
  • EUR 225.60
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) Polyclonal Antibody (Human)

4-PAA150Hu03
  • EUR 225.60
  • EUR 1903.20
  • EUR 498.00
  • EUR 271.20
  • EUR 225.60
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human Carcinoembryonic Antigen (CEA)

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNC941260-100 100uL
EUR 238.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNC941260-500 500uL
EUR 652.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNC941291-100 100uL
EUR 238.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291),CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNC941291-500 500uL
EUR 652.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291),CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNC941292-100 100uL
EUR 238.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292),CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNC941292-500 500uL
EUR 652.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292),CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R) Antibody

BNC941983-100 100uL
EUR 279.6
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R) Antibody

BNC941983-500 500uL
EUR 654
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009) Antibody

BNC942054-100 100uL
EUR 279.6
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009) Antibody

BNC942054-500 500uL
EUR 654
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R) Antibody

BNC942055-100 100uL
EUR 279.6
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R) Antibody

BNC942055-500 500uL
EUR 654
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), CF594 conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNCA1260-250 250uL
EUR 459.6
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), APC conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNCA1291-250 250uL
EUR 459.6
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291),APC conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNCA1292-250 250uL
EUR 459.6
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292),APC conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R) Antibody

BNCA1983-250 250uL
EUR 472.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1983R), APC conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009) Antibody

BNCA2054-250 250uL
EUR 472.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), APC conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R) Antibody

BNCA2055-250 250uL
EUR 472.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/2055R), APC conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNCAP1260-100 100uL
EUR 238.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1260) Antibody

BNCAP1260-500 500uL
EUR 652.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 ( C66/1260), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNCAP1291-100 100uL
EUR 238.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1291) Antibody

BNCAP1291-500 500uL
EUR 652.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1291),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Carcinoembryonic Antigen (CEA) / CD66 (C66/1292) Antibody

BNCAP1292-100 100uL
EUR 238.8
Description: Primary antibody against Carcinoembryonic Antigen (CEA) / CD66 (C66/1292),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Efficiency of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Neighborhood Setting, Wisconsin, November-December 2020 

Repeating the BinaxNOW antigen take a look at for SARS-CoV-2 by two teams of readers inside 30 minutes resulted in excessive concordance (98.9%) in 2,110 encounters. BinaxNOW take a look at sensitivity was 77.2% (258/334) in comparison with real-time reverse transcription-polymerase chain response. Similar day antigen testing didn’t considerably enhance take a look at sensitivity whereas specificity remained excessive.

Rs2686344 and serum squamous cell carcinoma antigen may predict medical efficacy of neoadjuvant chemotherapy for cervical most cancers 

Goal: To guage the predictive worth of a single nucleotide polymorphism (SNP) rs2686344 and squamous cell carcinoma antigen (SCCAg) ranges within the medical efficacy of neoadjuvant chemotherapy (NACT) for cervical most cancers.

Strategies: A complete of 92 sufferers with stage IB2-IIIB carcinoma of the uterine cervix who acquired NACT remedy had been enrolled. The connection between the genotypes of SNP rs2686344 which is positioned on CAMKK2 on chromosome 12, SCCAg ranges and the response to NACT was analyzed. The connection between the SNP rs2686344 genotypes, SCCAg ranges, the response to NACT and the five-year survival price was evaluated.

Outcomes: The efficient group accounted for 84.85% in sufferers with low stage (≤3.5 ng/mL) of post-treatment SCCAg (post-SCCAg), whereas the ineffective group accounted for 15.15%. The post-SCCAg ranges and the genotypes of rs2686344 had been considerably correlated with NACT response (P = 0.003, and P = 0.006). In sufferers with CC or CT genotype of SNP rs2686344, efficient group accounted for 81.18%, whereas ineffective group accounted for 18.82%; For sufferers with TT genotype, efficient response group accounted for 28.57%, ineffective group accounted for 71.43%. Submit-SCCAg stage >3.5 ng/mL and TT genotype of SNP rs2686344 confirmed as unbiased threat elements for NACT response within the multivariate evaluation (P = 0.002, and P = 0.048). There was no vital distinction in 5-year general survival and 5-year disease-free survival between sufferers with completely different ranges of post-SCCAg, or amongst completely different rs2686344 genotypes.

Conclusion: The excessive stage of post-SCCAg (>3.5 ng/mL) and TT genotype of rs2686344 might counsel a better threat of poor response to NACT.

Antibody and antigen prevalence as indicators of ongoing transmission or elimination of visceral leishmaniasis: a modelling examine 

Background: Management of visceral leishmaniasis (VL) on the Indian subcontinent has been extremely profitable. Management efforts equivalent to indoor residual spraying and lively case detection will likely be scaled down and even halted over the approaching years. We explored how after scale-down, potential recurrence of VL instances could also be predicted based mostly on population-based surveys of antibody or antigenaemia prevalence.

Strategies: Utilizing a stochastic age-structured transmission mannequin of VL, we predicted tendencies in case incidence and biomarker prevalence over time after cutting down management efforts when the goal of three successive years with out VL instances has been achieved. Subsequent, we correlated biomarker prevalence with the prevalence of latest VL instances inside 10 years of scale-down.

Outcomes: Incidence of at least one new VL case in a inhabitants of 10,000 was extremely correlated with the seroprevalence and antigenaemia prevalence for the time being of scale-down, or one or two years afterwards. Receiver working attribute curves indicated that biomarker prevalence in adults offered essentially the most predictive data, and seroprevalence was a extra informative predictor of latest VL instances than antigenaemia prevalence. Thresholds for biomarker prevalence to foretell prevalence of latest VL instances with excessive certainty had been strong to variation in pre-control endemicity.

Dialogue: The chance of recrudescence of VL after cutting down management efforts will be monitored and mitigated by the use of population-based surveys. Our findings spotlight that speedy point-of-care diagnostic instruments to evaluate (ideally) seroprevalence or (in any other case) antigenaemia within the normal inhabitants may very well be a key ingredient of sustainable VL management.

Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein 

Most cancers-associated antigens will not be solely a very good marker for monitoring most cancers development however are additionally helpful for molecular goal remedy. In this examine, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal most cancers cells relative to noncancerous gland cells. We ready antigens composed of HT-29 colorectal most cancers cell lysates that had been adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells. Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon most cancers cells, however not with sodium butyrate-induced differentiated HT-29 cells.

Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon most cancers tissue specimens examined at numerous levels, however little or no immunoreactivity in noncancerous gland cells. Notably, excessive 12G5A immunoreactivity, which was decided as greater than 50% of colon most cancers cells intensively stained with 12G5A antibody, exhibited considerably increased affiliation with a poor general survival price of sufferers with colorectal most cancers (P = 0.0196) and unfavorable progression-free survival price of sufferers with colorectal most cancers (P = 0.0418). Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing evaluation, enzymatic deglycosylation, and tunicamycin remedy revealed that 12G5A acknowledged the glycosylated epitope on annexin A2 protein.

Our findings point out that 12G5A recognized a cancer-associated glycosylation epitope on annexin A2, whose expression was associated to unfavorable colorectal most cancers habits. KEY MESSAGE: • 12G5A monoclonal antibody acknowledged a colorectal cancer-associated epitope. • 12G5A antibody acknowledged the N-linked glycosylation epitope on annexin A2. • 12G5A immunoreactivity was associated to unfavorable colorectal most cancers habits.

, , , , , , , , , , , ,

Post navigation

Leave a Reply

Your email address will not be published. Required fields are marked *